Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | GGT1 | P19440 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18495754 | 1.00 | TACR1 (0.41) | TACR1TLR2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL20565184 | 0.99 | TACR1 (0.40) | TACR1TLR2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL20565183 | 0.99 | TACR1 (0.40) | TACR1TLR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17006185 | 0.83 | TACR1 (0.39) | TACR1TLR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17006186 | 0.83 | TACR1 (0.39) | TACR1TLR2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18495748 | 0.82 | CYP3A4 (0.40) | — | |
| SCHEMBL18495741 | 0.82 | CYP3A4 (0.40) | — | |
| SCHEMBL17848454 | 0.77 | TACR1 (0.51) | TACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22890959 | 0.73 | NAAA (0.40) | TACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5471268 | 0.72 | TSHR (0.54) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10138253-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2018-11-27 | — | — | US | disclosed |
| EP-3334741-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-06-20 | — | — | EP | disclosed |
| WO-2017025913-A1 | IMIDAZOPYRIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138253-B2 | Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication | TYMP, TYMS, CCNI | TACR1 4405/4885TLR2 4664/4885SLC6A2 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.